- Home
- DHY vs TRDA Comparison
DHY vs TRDA Comparison
Compare DHY & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- TRDA
- Stock Information
- Founded
- DHY 1998
- TRDA 2016
- Country
- DHY United States
- TRDA United States
- Employees
- DHY N/A
- TRDA N/A
- Industry
- DHY Finance/Investors Services
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- TRDA Health Care
- Exchange
- DHY Nasdaq
- TRDA Nasdaq
- Market Cap
- DHY 220.7M
- TRDA 220.1M
- IPO Year
- DHY N/A
- TRDA 2021
- Fundamental
- Price
- DHY $2.09
- TRDA $5.27
- Analyst Decision
- DHY
- TRDA Strong Buy
- Analyst Count
- DHY 0
- TRDA 3
- Target Price
- DHY N/A
- TRDA $25.67
- AVG Volume (30 Days)
- DHY 569.1K
- TRDA 254.4K
- Earning Date
- DHY 01-01-0001
- TRDA 08-06-2025
- Dividend Yield
- DHY 9.10%
- TRDA N/A
- EPS Growth
- DHY N/A
- TRDA N/A
- EPS
- DHY N/A
- TRDA N/A
- Revenue
- DHY N/A
- TRDA $79,476,000.00
- Revenue This Year
- DHY N/A
- TRDA N/A
- Revenue Next Year
- DHY N/A
- TRDA N/A
- P/E Ratio
- DHY N/A
- TRDA N/A
- Revenue Growth
- DHY N/A
- TRDA N/A
- 52 Week Low
- DHY $1.77
- TRDA $4.93
- 52 Week High
- DHY $2.08
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- DHY 38.77
- TRDA 35.49
- Support Level
- DHY $2.11
- TRDA $5.09
- Resistance Level
- DHY $2.14
- TRDA $5.47
- Average True Range (ATR)
- DHY 0.02
- TRDA 0.42
- MACD
- DHY -0.00
- TRDA -0.03
- Stochastic Oscillator
- DHY 0.00
- TRDA 18.09
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.